Abstract: Objective To investigate the effects of valsartan combined with spironolactone on the treatment of intractable heart failure, coagulation function and cardiac function. Methods Eighty patients with intractable heart failure at the Department of Cardiology, Chifeng Cancer Hospital from January 2019 to December 2020 were involved and randomly divided into control group and experimental group, and each group contained 40 patients. The control group were treated with valsartan, while experimental group was also administrated with spironolactone in addition to valsartan. Response rated of different therapeutic schemes, and the improvement of coagulation indexes, cardiac function, ET-1 and NO levels and improvement of life quality from patients were compared herein. Results Response rate of experimental group was higher than control group,the difference was statistically significant (P<0.05). At the same time, after treatment the levels of D-dimer (D-D) and von Willebrand factor (vWF) in the control group were significantly lower than those in the control group. But the level of activated partial thromboplastin time (APTT) was significantly higher than that of the control group, the levels of left ventricular ejection fraction (LVEF) and output per stroke (SV) were significantly higher than those of the control group, and the level of heart rate (HR) was significantly lower than that of the control group. There was statistically significant difference between the two groups (P<0.05). After treatment, the level of ET-1 in the experimental group was significantly lower than that in the control group, while the level of NO in the experimental group was statistically significantly higher than that in the control group (P<0.05). The scores of physical function, psychological state, material life and life quality of social relations in the experimental group were higher than those in the control group after clinical treatment, and the difference was statistically significant (P<0.05). Conclusion Valsartan combined with spironolactone in the treatment of patients with intractable heart failure possessed high therapeutic efficacy, and the indexes of coagulation function, cardiac function and the levels of ET-1 and NO were significantly improved after treatment, which showed the potential to improve the life quality of patients and afforded high value of popularization and application.

Key words: Valsartan, spironolactone, intractable heart failure, coagulation function, cardiac function